Suchergebnisse - "optimal treatment duration"

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Autoren: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey et al.

Weitere Verfasser: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey et al.

Quelle: Acta Oncologica, Vol 64 (2025)
Acta oncologica
ACTA ONCOLOGICA

Schlagwörter: Male, Immune Checkpoint Inhibitors/administration & dosage, Radiology, Nuclear Medicine and Imaging, Time Factors, Oncologie, THERAPY, Carcinoma, Renal Cell/secondary, immune checkpoint inhibitors, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Ipilimumab/administration & dosage, Human health sciences, Kidney Neoplasms/mortality, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, OUTCOMES, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carcinoma, Renal Cell/pathology, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Kidney Neoplasms, Progression-Free Survival, Renal cell carcinoma, Nivolumab/administration & dosage, treatment discontinuation, Carcinoma, Renal Cell/mortality, Kidney Neoplasms/drug therapy, Nivolumab, optimal treatment duration, Oncology, Female, Life Sciences & Biomedicine, Adult, DISCONTINUATION, Sciences de la santé humaine, Kidney Neoplasms/pathology, Immune Checkpoint Inhibitors/adverse effects, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Carcinoma, Renal Cell, Retrospective Studies, Aged, Science & Technology, Duration of Therapy, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, MELANOMA PATIENTS, Carcinoma, Renal Cell/drug therapy, Human medicine, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://doaj.org/article/f0b66be9934249d38e034df42f696b62
https://hdl.handle.net/2268/335276
https://doi.org/10.2340/1651-226X.2025.43876
https://repository.uantwerpen.be/docstore/d:irua:30312
https://hdl.handle.net/10067/2161490151162165141
http://hdl.handle.net/1942/46632
http://hdl.handle.net/1854/LU-01K3QQRTE94KZYP1CX1X0WZ5CD
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD/file/01K42SV66F3YD38FGWT899GJ86
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD
http://doi.org/10.2340/1651-226x.2025.43876

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials

Autoren: Imperial, Marjorie Z Phillips, Patrick PJ Nahid, Payam et al.

Quelle: American Journal of Respiratory and Critical Care Medicine. 204(9)

Schlagwörter: Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Infectious Diseases, Clinical Trials and Supportive Activities, Emerging Infectious Diseases, Tuberculosis, Orphan Drug, Precision Medicine, Clinical Research, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Antitubercular Agents, Clinical Trials as Topic, Drug Administration Schedule, Duration of Therapy, Female, Humans, Male, Practice Guidelines as Topic, Rifampin, Risk Assessment, Tuberculosis, Pulmonary, Young Adult, tuberculosis therapeutics, risk stratification, stratified medicine, optimal treatment duration, clinical trial design, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/7c92h95n
https://escholarship.org/content/qt7c92h95n/qt7c92h95n.pdf

Increasing the power of randomized trials comparing different treatment durations

Autoren: Yongdong Ouyang Hong Qian Lakshmi N. Yatham et al.

Quelle: Contemporary Clinical Trials Communications, Vol 19, Iss , Pp 100588- (2020)

Schlagwörter: Clinical trial, Sample size, Multiple primary comparisons, Optimal treatment duration, Power, Time-dependent Cox PH model, Medicine (General), R5-920

Dateibeschreibung: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2451865420300727; https://doaj.org/toc/2451-8654

Zugangs-URL: https://doaj.org/article/1ac7c440bad24e97885cba6398d8ea47

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.

Autoren: Kim DDH Novitzky-Basso I Kim TS et al.

Quelle: British journal of haematology [Br J Haematol] 2021 May; Vol. 193 (4), pp. 779-791. Date of Electronic Publication: 2021 Apr 20.

Publikationsart: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

MeSH-Schlagworte: Imatinib Mesylate/*administration & dosage , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*mortality , Protein Kinase Inhibitors/*administration & dosage, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Canada/epidemiology ; Child ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Survival Rate